Agenus to trim its staff num­bers and as­sets

Agenus is look­ing to go all in on its lead sol­id tu­mor com­bo, but it will ef­fec­tive­ly halt work on its oth­er as­sets and cut 25% of its staff.

William Blair an­a­lysts said the com­pa­ny is cut­ting over 85 po­si­tions. Agenus told End­points News had it 365 em­ploy­ees.

The Lex­ing­ton, MA-head­quar­tered com­pa­ny will fo­cus on its CT­LA-4 an­ti­body boten­sil­imab plus PD-1 an­ti­body bal­stil­imab com­bo in a push for com­mer­cial­iza­tion. Agenus will di­vert all its R&D, reg­u­la­to­ry, qual­i­ty and man­u­fac­tur­ing ef­forts on the com­bo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER